Stryker Announces FDA Clearance Of Trevo Pro Retrieval System

Stryker Neurovascular announced today that its Trevo^® Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo^® Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever^® Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.